Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Financing Activities (2016 - 2025)

Altimmune (ALT) has disclosed Cash from Financing Activities for 16 consecutive years, with $81.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 704.46% to $81.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $206.8 million through Dec 2025, up 1959.36% year-over-year, with the annual reading at $206.8 million for FY2025, 1959.36% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $81.1 million at Altimmune, up from $39.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $81.1 million in Q4 2025, with the low at -$302000.0 in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $21.2 million, with a median of $12.8 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 169295.35% in 2023, while the deepest fall reached 109.49% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $12.5 million in 2021, then tumbled by 100.34% to -$43000.0 in 2022, then skyrocketed by 169295.35% to $72.8 million in 2023, then plummeted by 86.14% to $10.1 million in 2024, then soared by 704.46% to $81.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $81.1 million, $39.3 million, and $52.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.